(3-Chlorophenyl)-(6,7-dimethoxyquinoxalin-2-yl)-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (3-Chlorophenyl)-(6,7-dimethoxyquinoxalin-2-yl)-amine
• 英文别名: (3-Chloro-phenyl)-(6,7-dimethoxy-quinoxalin-2-yl)-amine；N-(3-chlorophenyl)-6,7-dimethoxyquinoxalin-2-amine
• 化学式: C₁₆H₁₄ClN₃O₂
• 分子量: 315.759
• InChiKey: GFHOQPFRWWTZIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  56.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-氯苯胺 、 2-氯-6,7-二甲氧基喹噁啉 生成 (3-Chlorophenyl)-(6,7-dimethoxyquinoxalin-2-yl)-amine
  参考文献：
  名称：

  Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR Exploration and Effective Bioisosteric Replacement of a phenyl substituent

  摘要：

  Novel substituted 2-anilino- and 2-cycloalkylaminoquinoxalines have been found to be useful and selective inhibitors of PDGF-R autophosphorylation. Replacement of an anilino-substituent with substituted cyclohexylamino- or norbornylamino substituents led to significant improvements in the pharmacokinetic profile of these analogues. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00654-1

文献信息

• [EN] QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56 TYROSINE KINASES<br/>[FR] COMPOSES QUINOLINE ET QUINOXALINE INHIBANT LE FACTEUR DE CROISSANCE DERIVE DES PLAQUETTES ET/OU LES TYROSINE-KINASES P56
  申请人：RHONE-POULENC RORER PHARMACEUTICALS, INC.

  公开号：WO1998054156A1

  公开（公告）日：1998-12-03

  (EN) This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.(FR) L'invention concerne des composés quinoline/quinoxaline inhibant la tyrosine-kynase de facteur de croissance dérivé des plaquettes et/ou la tyrosine-kinase Lck, des compositions pharmaceutiques renfermant ces composés, et l'utilisation de ces composés pour le traitement de patients souffrant ou sujets à des troubles/états associés à la différentiation et à la prolifération cellulaire, à la production de la matrice extracellulaire ou à la libération des médiateurs chimiques et/ou à l'activation et à la prolifération des lymphocytes T.

  该发明涉及抑制血小板衍生生长因子酪氨酸激酶和/或Lck酪氨酸激酶的喹啉/喹噁啉化合物，以及包含这些化合物的制药组合物，以及使用这些化合物治疗患有或受到涉及细胞分化、增殖、细胞外基质产生或介质释放和/或T细胞活化和增殖的疾病/病症的患者。
• Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
  申请人：Myers R. Michael

  公开号：US20050182054A1

  公开（公告）日：2005-08-18

  This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

  本发明涉及对喹啉/喹噁啉化合物的使用，该化合物抑制血小板源性生长因子酪氨酸激酶和/或Lck酪氨酸激酶，以及包含这些化合物的药物组合物，并用于治疗患有或受到涉及细胞分化、增殖、细胞外基质产生或介质释放以及/或T细胞激活和增殖的疾病/状况的患者。
• QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES
  申请人：RHONE-POULENC RORER PHARMACEUTICALS, INC.

  公开号：EP0991628A1

  公开（公告）日：2000-04-12
• QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
  申请人：Aventis Pharmaceuticals Inc

  公开号：EP0991628B1

  公开（公告）日：2005-01-12
• EP0991628A4
  申请人：——

  公开号：EP0991628A4

  公开（公告）日：2000-07-26